泽璟制药(688266) - 2021 Q1 - 季度财报

Financial Performance - Net profit attributable to shareholders of the listed company was -CNY 79,712,996.47, compared to -CNY 62,262,940.60 in the same period last year[18]. - Basic and diluted earnings per share were both -CNY 0.33, compared to -CNY 0.28 in the same period last year[18]. - The company reported no operating revenue for the current period[18]. - The weighted average return on net assets was -5.03%, slightly down from -4.98% in the previous year[18]. - Net loss for Q1 2021 was 83,131,384.17 RMB, compared to a net loss of 65,385,205.55 RMB in Q1 2020, indicating a worsening of approximately 27%[53]. - The company reported an operating profit of -83,956,666.09 RMB for Q1 2021, compared to -66,479,383.97 RMB in Q1 2020, indicating a worsening of approximately 26%[52]. - Total comprehensive loss for Q1 2021 was CNY 76,407,616.71, compared to a loss of CNY 59,341,419.63 in Q1 2020[60]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,915,773,589.48, a decrease of 2.77% compared to the end of the previous year[18]. - Total assets at the end of the reporting period amounted to RMB 1,602,462,510.19, a decrease from RMB 1,669,567,723.00 at the end of the previous year[37]. - Total assets decreased to CNY 1,915,773,589.48 from CNY 1,970,281,983.90, a decline of approximately 2.8%[40]. - Current liabilities increased to CNY 163,748,934.85 from CNY 140,877,117.87, representing an increase of about 16.2%[40]. - The company's total liabilities increased to CNY 300,368,161.17 from CNY 278,692,214.57, an increase of about 7.2%[42]. - The total liabilities increased to 317,970,353.39 RMB in the latest report from 297,395,912.49 RMB previously, showing a rise of about 7%[48]. - Total equity decreased to 1,539,373,712.52 RMB from 1,609,846,225.54 RMB, reflecting a decline of approximately 4.3%[48]. - The company's total current assets decreased to CNY 1,540,785,446.12 from CNY 1,606,196,149.75, a decrease of approximately 4.1%[46]. Cash Flow - Net cash flow from operating activities was -CNY 102,692,920.27, compared to -CNY 77,046,755.90 in the same period last year[18]. - The company’s cash flow from investing activities was RMB 302,344,608.78, a significant recovery from -RMB 743,098,354.19 in the previous year[33]. - Cash flow from operating activities showed a net outflow of CNY 102,692,920.27 in Q1 2021, worsening from a net outflow of CNY 77,046,755.90 in Q1 2020[62]. - Cash inflow from investment activities totaled 503,378,643.38 RMB in Q1 2021, a significant increase from 6,274,568.75 RMB in Q1 2020, representing a growth of over 7,900%[66]. - The net cash flow from investment activities was 302,344,608.78 RMB in Q1 2021, compared to -742,997,474.84 RMB in Q1 2020, showing a substantial improvement[66]. Shareholder Information - The total number of shareholders at the end of the reporting period was 10,612[23]. - The largest shareholder, ZELIN SHENG, held 20.68% of the shares, totaling 49,636,620 shares[23]. Research and Development - R&D expenses increased by 38.57% to RMB 83,863,240.72, driven by higher clinical research service costs and growth in R&D personnel[30]. - The company expects to continue incurring losses until the end of the reporting period due to ongoing R&D investments and the establishment of a commercial sales team[32]. - The company is currently awaiting approval for its first new drug application (NDA), with multiple innovative drug projects progressing steadily[32]. Expenses - Sales expenses increased by 182.72% to RMB 11,630,597.38, due to the expansion of the sales team and pre-launch market activities for new drugs[30]. - Operating costs for Q1 2021 were 98,558,109.45 RMB, compared to 73,021,269.57 RMB in Q1 2020, indicating a significant rise in expenses[52]. - Sales expenses for Q1 2021 were CNY 11,977,334.13, significantly higher than CNY 4,200,060.34 in Q1 2020, reflecting an increase of approximately 185%[58]. Financial Position - The company's financial assets decreased by 68.83% to RMB 140,234,107.87, primarily due to changes in bank principal-protected financial products[30]. - Short-term borrowings rose significantly by 172.26% to RMB 48,106,880.18, reflecting increased working capital needs[30]. - The company's long-term borrowings remained stable at CNY 30,033,733.33[40]. - The company's intangible assets decreased to CNY 123,127,354.66 from CNY 129,513,660.91, a decline of about 4.9%[40].